POINT Biopharma Global Inc. (NASDAQ:PNT – Get Rating) shares gapped up before the market opened on Monday . The stock had previously closed at $9.14, but opened at $9.59. POINT Biopharma Global shares last traded at $6.52, with a volume of 8,412 shares changing hands.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on PNT shares. Berenberg Bank initiated coverage on shares of POINT Biopharma Global in a research note on Wednesday, September 14th. They issued a “buy” rating and a $20.00 target price for the company. Jonestrading initiated coverage on POINT Biopharma Global in a research note on Tuesday, September 6th. They set a “buy” rating for the company. Oppenheimer started coverage on POINT Biopharma Global in a research note on Monday, October 10th. They issued an “outperform” rating and a $20.00 price target on the stock. Guggenheim increased their price target on POINT Biopharma Global from $20.00 to $22.00 in a report on Monday, September 12th. Finally, Piper Sandler dropped their price objective on POINT Biopharma Global from $17.00 to $14.00 in a report on Monday. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, POINT Biopharma Global has a consensus rating of “Moderate Buy” and a consensus target price of $24.56.
POINT Biopharma Global Price Performance
The business has a fifty day moving average of $8.34 and a 200-day moving average of $8.04.
Institutional Inflows and Outflows
About POINT Biopharma Global
POINT Biopharma Global Inc, a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.
- Get a free copy of the StockNews.com research report on POINT Biopharma Global (PNT)
- Power Integrations Stock Can Power Your Portfolio
- Don’t Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe’s?
- Agilent Remains In Buy Range Ahead Of Next Week’s Q4 Report
- Three Penny Stocks Making Big Moves In November
Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.